Biomarin Pharmaceutical - Registered Shares Long Term Debt

As of the most recent data (March 2026), BMRN shows a long-term debt of $1.4B. That compares with $600M in the prior-year period — up 140.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BMRN's long-term debt is now $1.4B (was $600M) — a 140.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Biomarin Pharmaceutical - Registered Shares is outperforming or lagging.

Tracking BMRN's long-term debt over time shows whether Biomarin Pharmaceutical - Registered Shares is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4B That compares with $600M in the prior-year period — up 140.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Biomarin Pharmaceutical - Registered Shares's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.4B) with ownership activity and broader fundamentals.

Biomarin Pharmaceutical - Registered Shares's long-term debt is $1.4B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.